consider and approve the unaudited financial result for the quarter and half year ended on 30.09.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 0.5 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Archit Organosys reported Q2 FY26 revenue from operations of Rs. 32.86 crore, up about 11% YoY from Rs. 29.54 crore in Q2 FY25. For the half year, revenue rose 16.8% YoY to Rs. 66.06 crore versus Rs. 56.54 crore last year. Net profit jumped around 52% YoY in Q2 to Rs. 1.54 crore and nearly 77% YoY for H1 to Rs. 3.58 crore, with earnings per share for H1 at Rs. 1.74 vs Rs. 0.99 earlier. Operating cash flow remained positive at Rs. 3.44 crore in H1 FY26, while total expenses grew more slowly than revenue, lifting margins. The statutory auditor issued an unqualified review report with no qualifications, and no exceptional items were recorded.
Sharply higher profits on steady revenue and improving margins are positive for shareholders; the clean auditor report and positive cash flow reinforce a healthy operating picture, even though topline growth is below 20%.